Related Experiment Videos
[Cyclophosphamide pulse therapy for pediatric systemic sclerosis]
Naomi Iwata1, Takako Miyamae, Tomoyuki Imagawa
1Department of Pediatrics and Dermatology, Yokohama City University School of Medicine, Yokohama, Japan.
Ryumachi. [Rheumatism]
|November 6, 2003
Summary
Early cyclophosphamide pulse therapy significantly improved pediatric systemic sclerosis, including interstitial pneumonia and skin scores. Delayed treatment in one patient was less effective, highlighting the importance of timely intervention for better outcomes.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Dermatology
Background:
- Systemic sclerosis is a rare autoimmune disease affecting children.
- Early diagnosis and intervention are crucial for managing pediatric systemic sclerosis.
- Treatment options for pediatric systemic sclerosis are continuously being evaluated.
Observation:
- Three pediatric patients with systemic sclerosis were analyzed.
- Two patients received early intravenous cyclophosphamide pulse therapy.
- One patient received delayed immunosuppressive therapy after initial vitamin E treatment.
Findings:
- Early cyclophosphamide pulse therapy led to dramatic improvement in interstitial pneumonia, scleroderma, and total skin score in two patients.
- Pulmonary hypertension in one patient stabilized with early cyclophosphamide treatment.
- The patient receiving delayed treatment showed persistent severe disease and ultimately did not survive.
Implications:
- Early cyclophosphamide pulse therapy appears to be an effective induction treatment for pediatric systemic sclerosis.
- Timely intervention with cyclophosphamide may improve clinical manifestations and prevent disease progression.
- Further research is warranted to optimize treatment strategies for pediatric systemic sclerosis.